BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company ...

Q4 2024 Earnings Call Mar 10, 2025, 8:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants. P ...

BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioNTech SE (BNTX – Research Report) and ...

BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key ...

KEY TAKEAWAYS U.S.-listed shares of BioNTech fell Monday, as the COVID-19 vaccine maker’s soft sales outlook offset ...

Shares of German biotech BioNTech (Nasdaq: BNTX) dipped 2.5% to $105.86 today, after it reported financial results for the ...

For 2025, BioNTech management anticipates revenue between 1.7 billion euros and 2.2 billion euros, with planned R&D outlays reaching between 2.6 billion euros and 2.8 billion euros. The company's ...

The full audited consolidated financial statements as of and for the year ended December 31, 2024, can be found in BioNTech's Annual Report on Form 20-F filed today with the United States Securities ...

BioNTech (BNTX) reported a decline in fourth-quarter revenue and projected full-year sales to fall again in 2025, while the German drugmaker announced plans to ramp up research and development efforts ...

German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ...

German biotech firm's revenues down 27% compared to 2023, according to company's financial report - Anadolu Ajansı ...